Skip to main content
Erschienen in: MMW - Fortschritte der Medizin 9/2014

13.05.2014 | FORTBILDUNG_SCHWERPUNKT

Das geht an die Nieren!

Schlechte Blutzuckereinstellung bei Diabetes mellitus

verfasst von: Dr. med. Christiane Drechsler, Dr. med. Andreas Schneider, Dr. med. Kay-Renke Schmidt, Prof. Dr. med. Christoph Wanner

Erschienen in: MMW - Fortschritte der Medizin | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die diabetesassoziierte Nephropathie (DNP) ist eine direkte Folgeerkrankung der diabetischen Stoffwechselstörung, die zu einer Angiopathie der Kapillaren des Nierenkörperchens (Glomerulum) führt. Aber nicht alle Diabetiker sind betroffen. Lesen Sie, wer besonders gefährdet ist und was Sie tun können.
Literatur
1.
Zurück zum Zitat Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 1989;4(10):859–863 Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 1989;4(10):859–863
3.
Zurück zum Zitat Hasslacher C et al. Nephropathie bei Diabetes. Diabetologie 2013;8:S119–S122 CrossRef Hasslacher C et al. Nephropathie bei Diabetes. Diabetologie 2013;8:S119–S122 CrossRef
4.
Zurück zum Zitat de Zeeuw D, Akizawa T, Audhya Pet al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. The New England journal of medicine. Dec 26 2013;369(26):2492–2503. PubMedCrossRef de Zeeuw D, Akizawa T, Audhya Pet al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. The New England journal of medicine. Dec 26 2013;369(26):2492–2503. PubMedCrossRef
5.
Zurück zum Zitat Parving HH, Brenner BM, McMurray JJet al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. The New England journal of medicine 2012;367(23):2204–2213 PubMedCrossRef Parving HH, Brenner BM, McMurray JJet al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. The New England journal of medicine 2012;367(23):2204–2213 PubMedCrossRef
6.
Zurück zum Zitat Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England journal of medicine 2004;351(13):1296–1305 PubMedCrossRef Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England journal of medicine 2004;351(13):1296–1305 PubMedCrossRef
7.
Zurück zum Zitat Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney international 2003;63(4): 1468–1474 PubMedCrossRef Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney international 2003;63(4): 1468–1474 PubMedCrossRef
8.
Zurück zum Zitat van der Velde M, Matsushita K, Coresh J et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney international 2011; 79(12):1341–1352. PubMedCrossRef van der Velde M, Matsushita K, Coresh J et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney international 2011; 79(12):1341–1352. PubMedCrossRef
9.
Zurück zum Zitat Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of internal medicine 2001;134(8):629–636 PubMedCrossRef Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of internal medicine 2001;134(8):629–636 PubMedCrossRef
10.
Zurück zum Zitat Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. CJASN 2007;2(6):1306–1316 PubMed Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. CJASN 2007;2(6):1306–1316 PubMed
12.
Zurück zum Zitat Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Annals of internal medicine 2013;158(11):825–830 PubMedCrossRef Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Annals of internal medicine 2013;158(11):825–830 PubMedCrossRef
14.
Zurück zum Zitat Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54(6):1615–1625 PubMedCrossRef Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54(6):1615–1625 PubMedCrossRef
15.
Zurück zum Zitat Tervaert TW, Mooyaart AL, Amann K et al. Pathologic classification of diabetic nephropathy. JASN 2010;21(4):556–563. PubMedCrossRef Tervaert TW, Mooyaart AL, Amann K et al. Pathologic classification of diabetic nephropathy. JASN 2010;21(4):556–563. PubMedCrossRef
16.
Zurück zum Zitat Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870–878 PubMedCrossRef Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870–878 PubMedCrossRef
17.
Zurück zum Zitat Drury PL, Smith GM Ferriss JB. Increased vasopressor responsiveness to aniotensin II in type 1 (insulin-dependent) diabetic patients without complications. Diabetologia 1984;27:174–179. PubMed Drury PL, Smith GM Ferriss JB. Increased vasopressor responsiveness to aniotensin II in type 1 (insulin-dependent) diabetic patients without complications. Diabetologia 1984;27:174–179. PubMed
18.
Zurück zum Zitat Hollenberg NK, Price DA, Fisher NDet al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney international 2003;63(1):172–178 PubMedCrossRef Hollenberg NK, Price DA, Fisher NDet al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney international 2003;63(1):172–178 PubMedCrossRef
19.
Zurück zum Zitat Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. JASN 2005; 16(4):1135–1140 PubMedCrossRef Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. JASN 2005; 16(4):1135–1140 PubMedCrossRef
20.
Zurück zum Zitat Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. The Cochrane database of systematic reviews 2010(4):CD002967. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. The Cochrane database of systematic reviews 2010(4):CD002967.
21.
Zurück zum Zitat Ekstrom N, Schioler L, Svensson AMet al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ open 2012;2(4) Ekstrom N, Schioler L, Svensson AMet al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ open 2012;2(4)
22.
Zurück zum Zitat Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes care 2011; 34(6):1431–1437 PubMedCentralPubMedCrossRef Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes care 2011; 34(6):1431–1437 PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977–986 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977–986
25.
Zurück zum Zitat Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes care 1999; 22(1):99–111 Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes care 1999; 22(1):99–111
26.
Zurück zum Zitat DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;22;365(25):2366–2376 DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;22;365(25):2366–2376
27.
Zurück zum Zitat Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12):861–869 PubMedCrossRef Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12):861–869 PubMedCrossRef
28.
Zurück zum Zitat Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851–860 PubMedCrossRef Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851–860 PubMedCrossRef
29.
Zurück zum Zitat Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15): 1547–1559 PubMedCrossRef Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15): 1547–1559 PubMedCrossRef
30.
Zurück zum Zitat Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369(20):1892–1903 PubMedCrossRef Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369(20):1892–1903 PubMedCrossRef
31.
Zurück zum Zitat 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. Journal of hypertension 2013;31(10):1925–1938 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. Journal of hypertension 2013;31(10):1925–1938
32.
Zurück zum Zitat KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney international 2014 KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney international 2014
33.
Zurück zum Zitat Locatelli F, Barany P, Covic Aet al. Kidney Disease. Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association. European Renal Association 2013;28 (6):1346–1359 Locatelli F, Barany P, Covic Aet al. Kidney Disease. Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association. European Renal Association 2013;28 (6):1346–1359
Metadaten
Titel
Das geht an die Nieren!
Schlechte Blutzuckereinstellung bei Diabetes mellitus
verfasst von
Dr. med. Christiane Drechsler
Dr. med. Andreas Schneider
Dr. med. Kay-Renke Schmidt
Prof. Dr. med. Christoph Wanner
Publikationsdatum
13.05.2014
Verlag
Urban & Vogel
Erschienen in
MMW - Fortschritte der Medizin / Ausgabe 9/2014
Print ISSN: 1438-3276
Elektronische ISSN: 1613-3560
DOI
https://doi.org/10.1007/s15006-014-2867-3

Weitere Artikel der Ausgabe 9/2014

MMW - Fortschritte der Medizin 9/2014 Zur Ausgabe

FORTBILDUNG_ÜBERSICHT

Schon zu alt für eine OP?

AKTUELLE MEDIZIN_DER BESONDERE FALL

Myokarditis — was sonst?

Newsletter

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Allgemeinmedizin und bleiben Sie gut informiert – ganz bequem per eMail.